KindlyMD (NASDAQ:NAKA) CEO Acquires $507,391.72 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 104,833 shares of KindlyMD stock in a transaction on Wednesday, May 27th. The shares were bought at an average cost of $4.84 per share, with a total value of $507,391.72. Following the completion of the purchase, the chief executive officer owned 3,120,361 shares in the company, valued at $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

KindlyMD Stock Up 11.8%

NAKA opened at $6.26 on Friday. The business has a 50 day moving average price of $8.14 and a two-hundred day moving average price of $13.02. The company has a market cap of $108.92 million, a PE ratio of -0.14 and a beta of 17.12. KindlyMD, Inc. has a 52 week low of $4.50 and a 52 week high of $995.60.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The company had revenue of $2.68 million for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. As a group, sell-side analysts expect that KindlyMD, Inc. will post -16.8 EPS for the current fiscal year.

Hedge Funds Weigh In On KindlyMD

A number of large investors have recently modified their holdings of NAKA. Sagespring Wealth Partners LLC purchased a new position in shares of KindlyMD during the 4th quarter worth approximately $28,000. SG Americas Securities LLC purchased a new position in KindlyMD in the 4th quarter valued at approximately $61,000. Virtu Financial LLC purchased a new position in KindlyMD in the 4th quarter valued at approximately $151,000. J. Derek Lewis & Associates Inc. purchased a new position in KindlyMD in the 4th quarter valued at approximately $167,000. Finally, Truist Financial Corp purchased a new position in KindlyMD in the 4th quarter valued at approximately $176,000.

Wall Street Analyst Weigh In

NAKA has been the subject of a number of analyst reports. B. Riley Financial cut their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. TD Cowen initiated coverage on KindlyMD in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 target price for the company. Maxim Group cut their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, KindlyMD presently has an average rating of “Hold” and an average price target of $30.00.

Trending Headlines about KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.